Proteomic and genomic profiling of pancreatic cancer

Abstract

Pancreatic cancer remains the most fatal human tumor type. The aggressive tumor biology coupled with the lack of early detection strategies and effective treatment are major reasons for the poor survival rate. Collaborative research efforts have been devoted to understand pancreatic cancer at the molecular level. Large-scale genomic studies have generated important insights into the genetic drivers of pancreatic cancer. In the post-genomic era, protein sequencing of tumor tissue, cell lines, pancreatic juice, and blood from patients with pancreatic cancer has provided a fundament for the development of new diagnostic and prognostic biomarkers. The integration of mass spectrometry and genomic sequencing strategies may help characterize protein identities and post-translational modifications that relate to a specific mutation. Consequently, proteomic and genomic techniques have become a compulsory requirement in modern medicine and health care. These types of proteogenomic studies may usher in a new era of precision diagnostics and treatment in patients with pancreatic cancer.

The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response

“…Protein expression patterns in PDAC liver metastases also have the potential to reveal new associations with clinical outcomes or identify novel therapeutic targets (14,31). With the understanding that PDAC is not a singular disease, we hypothesized that associations between protein expression and patient survival might display subtype-specific characteristics.…”

“…There have been comparative proteomics studies on PDAC that have identified proteins from tissue, plasma, pancreatic juice, cyst fluid, and urine associated with this disease. These efforts illustrate the potential of applying proteomics approaches to improve early detection and treatment of PDAC based on single proteins (13,14). IHC evaluating expressions of only KRT81 and HNF1A proteins has been used to stratify PDAC tumors as either classical, quasi-mesenchymal, or exocrine-like (15).…”

Proteogenomic Analysis of Pancreatic Cancer Subtypes

“…Equally, no studies of pancreatic cancer have focused explicitly on segregating the patients based on the proteomic difference, and explored the subtype-specific alterations in the cellular processes and signalling pathways. Furthermore, recent studies have conducted a proteomic analysis of pancreatic cancer [20][21][22][23][24][25][26]; however, they have not integrated the proteomic subtypes with alterations in various signalling pathways, to the specific cancer gene mutations and/or the disease outcomes of the afflicted patients.…”

Identification of dissociation factors in pancreatic Cancer using a mass spectrometry-based proteomic approach

“…With the development of experimental techniques, the number of molecular detection methods for cancer is increasing. These methods play an important role in the early diagnosis of pancreatic cancer [6]. In a previous study, we used two cell lines derived from the hamster model of pancreatic cancer that have distinct invasion and metastasis abilities: a nondissociated, low-metastasis pancreatic cancer cell line (PC-1) and a dissociated, high-metastasis pancreatic cancer cell line (PC-1.0).…”